The effects of the modified MHP1 on tissue plasminogen activator (tPA)-induced thrombolysis and cerebral hemorrhage were also examined because tPA is commonly used in the acute stage of ischemic stroke clinically. The gene discussed is CACNA1A; the disease is ischemic stroke.